Knopp-Sihota Jennifer A, Cummings Greta G, Newburn-Cook Christine V, Homik Joanne, Voaklander Don
Faculty of Health Disciplines, Athabasca University, Edmonton, Alberta, Canada; Faculty of Nursing, University of Alberta, Edmonton, Alberta, Canada.
Geriatr Gerontol Int. 2014 Jan;14(1):121-9. doi: 10.1111/ggi.12069. Epub 2013 Aug 29.
Increasing age and a diagnosis of dementia both dramatically increase the risk of serious osteoporosis-related sequela. We sought to examine the factors associated with osteoporosis treatment, in relation to dementia diagnosis, in older adults with osteoporosis.
This was a population-based, retrospective, nested, case-control study utilizing administrative healthcare data from British Columbia, Canada. Community-based individuals aged ≥65 years with an osteoporosis diagnosis and continuous enrolment in the provinces' drug plan between 1991 and 2007 were eligible for inclusion. A multivariate logistic regression model was assembled to examine the relationship between dementia diagnosis, age, sex, other comorbidity, residence and osteoporosis medication dispensation.
Almost half of the total osteoporosis cohort (n = 39 452) were dispensed an osteoporosis medication during the study period. Individuals with no dementia diagnosis were dispensed a medication significantly more often than those with a diagnosis of dementia (P < 0.001). Those patients with dementia (n = 13 315), who had been dispensed an osteoporosis drug, were more often younger, female, had not sustained a previous fracture, had ≥ 4 comorbid conditions and lived in the most central health region (P < 0.001). A diagnosis of dementia was found to be a significant negative predictor of osteoporosis drug dispensation (adjusted OR 0.55; 95% CI 0.44-0.69). Increasing comorbidity was significantly associated with receiving treatment (adjusted OR 3.30; 95% CI 2.88-3.78).
Despite the wide availability of osteoporosis medications, our findings suggest that many older adults with a diagnosis of dementia, but not necessarily fewer comorbid conditions, were not receiving treatment.
年龄增长和痴呆症诊断均会显著增加严重骨质疏松相关后遗症的风险。我们试图研究骨质疏松症老年患者中与骨质疏松症治疗相关的因素,并与痴呆症诊断相关联。
这是一项基于人群的回顾性巢式病例对照研究,利用了加拿大不列颠哥伦比亚省的行政医疗保健数据。年龄≥65岁、诊断为骨质疏松症且在1991年至2007年期间持续参加该省药物计划的社区居民符合纳入条件。构建了一个多变量逻辑回归模型,以研究痴呆症诊断、年龄、性别、其他合并症、居住地与骨质疏松症药物配给之间的关系。
在研究期间,几乎一半的骨质疏松症队列患者(n = 39452)接受了骨质疏松症药物配给。未诊断为痴呆症的个体比诊断为痴呆症的个体更频繁地接受药物配给(P < 0.001)。那些接受过骨质疏松症药物配给的痴呆症患者(n = 13315)更年轻、女性居多、未曾发生过骨折、有≥4种合并症且居住在最中心的健康区域(P < 0.001)。发现痴呆症诊断是骨质疏松症药物配给的显著负向预测因素(调整后的比值比为0.55;95%置信区间为0.44 - 0.69)。合并症增加与接受治疗显著相关(调整后的比值比为3.30;95%置信区间为2.88 - 3.78)。
尽管骨质疏松症药物广泛可得,但我们的研究结果表明,许多诊断为痴呆症的老年人未接受治疗,而不一定是合并症较少的老年人。